RT Journal Article
SR Electronic
T1 Efficacy of Spirulina for Allergic Rhinitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.21.21265199
DO 10.1101/2021.10.21.21265199
A1 Batista, Iury Gomes
A1 Person, Osmar Clayton
A1 Bogar, Priscila
A1 Angélico Júnior, Fernando Veiga
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.21.21265199.abstract
AB Introduction Allergic rhinitis is a condition of high prevalence in the population and widely studied, with several treatments being consecrated for its control. Spirulina is a dietary supplement that modulates immune function, and has been shown to modulate the inflammatory response of allergic rhinitis.Purpose To evaluate spirulina in the treatment and control of allergic rhinitis.Material and Methods This is a systematic review of randomized clinical trials. Searches were performed for randomized clinical trials relating spirulina to allergic rhinitis in five electronic databases: Cochrane - Central Register of Controlled Trials - CENTRAL (2021), PUBMED (1966-2021), EMBASE (1974-2021), LILACS (1982-2021) AND SCOPUS (2021). Two investigators independently extracted data and assessed trial quality.Results Two clinical trials involving a total of 215 patients were included. Both studies assessed the efficacy of spirulina in improving allergic rhinitis as the primary outcome. The first study described a significant reduction in runny nose, nasal congestion and itching over time of medication use (p<0.001) and in the second study the prevalence of rhinorrhea (P = 0.021), nasal congestion or obstruction (P = 0.039) and decreased smell (P = 0.030) were significantly less in the experimental group than in the control group.Conclusions The included studies were in favor of the use of spirrulina. However, the level of evidence is very low and limited. We should have caution due to the small number of clinical trials and participants in these studies. It is recommended to carry out new RCTs following the CONSORT standardization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: University of ABC MEdicine FMABC Santo Andre Brazil All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. https://pubmed.ncbi.nlm.nih.gov/18343939/ https://pubmed.ncbi.nlm.nih.gov/32773785/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://pubmed.ncbi.nlm.nih.gov/18343939/ https://pubmed.ncbi.nlm.nih.gov/32773785/